Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2016 Apr 28;36(6):1090–1100. doi: 10.1161/ATVBAHA.115.306964

Figure 6. MtROS contribute to LPC-induced endothelial activation by upregulating nuclear binding of AP-1 on the promoter of ICAM-1.

Figure 6

A. Putative AP-1 and NFκB binding site in the promoter of ICAM-1. B & C. MtROS inhibitor MitoTEMPO blocked LPC-induced nuclear AP-1 binding. HAECs were treated with vehicle or LPC (10 μM) for 1 hour with or without MitoTEMPO (1 μM) 1-hour pre-incubation, and nuclear proteins were collected afterwards for electrophoretic mobility shift assay (EMSA). 2 μg nuclear proteins were used for AP-1 EMSA (B) and 5 μg nuclear proteins were used for NFκB EMSA (C). Representative images from three independent experiments were shown.